Although the aim of the Phase I/II trial was to evaluate the maximum tolerated dose (MTD) and the secondary aim was to evaluate safety and preliminary effects of the drug, the positive clinical results are pushing the company to pursue Phase III ...
http://www.medicaldaily.com/articles/16129/20130603/brca-target-brca-mutation-biomarin-drug-breast-cancer-ovarian-cancer.htm
BY WORLD DRUG TRACKER
DR ANTHONY CRASTO
http://www.medicaldaily.com/articles/16129/20130603/brca-target-brca-mutation-biomarin-drug-breast-cancer-ovarian-cancer.htm
BY WORLD DRUG TRACKER
DR ANTHONY CRASTO
No comments:
Post a Comment